188 related articles for article (PubMed ID: 21677471)
1. Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future.
Mulder K; Koski S; Scarfe A; Chu Q; King K; Spratlin J
Oncotarget; 2010 Nov; 1(7):515-529. PubMed ID: 21317448
[TBL] [Abstract][Full Text] [Related]
2. Personalized medicine in gastric cancer: Where are we and where are we going?
Jácome AA; Coutinho AK; Lima EM; Andrade AC; Dos Santos JS
World J Gastroenterol; 2016 Jan; 22(3):1160-71. PubMed ID: 26811654
[TBL] [Abstract][Full Text] [Related]
3. Molecular Pathways: Targeting the Microenvironment of Liver Metastases.
Milette S; Sicklick JK; Lowy AM; Brodt P
Clin Cancer Res; 2017 Nov; 23(21):6390-6399. PubMed ID: 28615370
[TBL] [Abstract][Full Text] [Related]
4. Targeting metastatic upper gastrointestinal adenocarcinomas.
Spratlin JL; Chu Q; Koski S; King K; Mulder K
World J Clin Oncol; 2011 Mar; 2(3):135-49. PubMed ID: 21611088
[TBL] [Abstract][Full Text] [Related]
5. Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs.
Xing P; Wang S; Cao Y; Liu B; Zheng F; Guo W; Huang J; Zhao Z; Yang Z; Lin X; Sang L; Liu Z
Drug Resist Updat; 2023 Nov; 71():101002. PubMed ID: 37678078
[TBL] [Abstract][Full Text] [Related]
6. Molecular diagnostics of hepatobiliary and pancreatic neoplasias.
Longerich T; Stenzinger A; Schirmacher P
Virchows Arch; 2024 Feb; 484(2):263-272. PubMed ID: 38429607
[TBL] [Abstract][Full Text] [Related]
7. Response Evaluation Criteria in Gastrointestinal and Abdominal Cancers: Which to Use and How to Measure.
Castagnoli F; Mencel J; Ap Dafydd D; Gough J; Drake B; Mcaddy NC; Withey SJ; Riddell AM; Koh DM; Shur JD
Radiographics; 2024 May; 44(5):e230047. PubMed ID: 38662587
[TBL] [Abstract][Full Text] [Related]
8. Editorial: New insights into molecular mechanisms and targeted therapy for gastrointestinal tumors.
Feng H; Li H; Chen M; Zhang T; Zhou Y; Xu Y; Zhang W; Zhang T
Front Cell Dev Biol; 2023; 11():1289530. PubMed ID: 37842088
[No Abstract] [Full Text] [Related]
9. CLIP-170S is a microtubule +TIP variant that confers resistance to taxanes by impairing drug-target engagement.
Thakkar PV; Kita K; Castillo UD; Galletti G; Madhukar N; Navarro EV; Barasoain I; Goodson HV; Sackett D; Díaz JF; Lu Y; RoyChoudhury A; Molina H; Elemento O; Shah MA; Giannakakou P
Dev Cell; 2021 Dec; 56(23):3264-3275.e7. PubMed ID: 34672971
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell engineering for selective targeting of female reproductive tract cancers.
Bhargava A; Srivastava RK; Mishra DK; Tiwari RR; Sharma RS; Mishra PK
Indian J Med Res; 2018 Dec; 148(Suppl):S50-S63. PubMed ID: 30964081
[TBL] [Abstract][Full Text] [Related]
11. Correlations between cytoplasmic CSE1L in neoplastic colorectal glands and depth of tumor penetration and cancer stage.
Tai CJ; Su TC; Jiang MC; Chen HC; Shen SC; Lee WR; Liao CF; Chen YC; Lin SH; Li LT; Shen KH; Yeh CM; Yeh KT; Lee CH; Shih HY; Chang CC
J Transl Med; 2013 Jan; 11():29. PubMed ID: 23369209
[TBL] [Abstract][Full Text] [Related]
12. Genetics and molecular pathology of gastric malignancy: Development of targeted therapies in the era of personalized medicine.
Van Ness M; Gregg J; Wang J; Chen M
J Gastrointest Oncol; 2012 Sep; 3(3):243-51. PubMed ID: 22943015
[TBL] [Abstract][Full Text] [Related]
13. K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy.
Stec R; Bodnar L; Charkiewicz R; Korniluk J; Rokita M; Smoter M; Ciechowicz M; Chyczewski L; Nikliński J; Kozłowski W; Szczylik C
Cancer Biol Ther; 2012 Nov; 13(13):1235-43. PubMed ID: 22909976
[TBL] [Abstract][Full Text] [Related]
14. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
15. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
16. Genetics of hepatobiliary carcinogenesis.
Nault JC; Zucman-Rossi J
Semin Liver Dis; 2011 May; 31(2):173-87. PubMed ID: 21538283
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies in gastrointestinal cancers.
Bronte G; Cicero G; Cusenza S; Galvano A; Musso E; Rizzo S; Sortino G; Roselli M; Bazan V; Fiorentino E; Russo A
Expert Opin Biol Ther; 2013 Jun; 13(6):889-900. PubMed ID: 23441760
[TBL] [Abstract][Full Text] [Related]
18. Predictors of response to targeted therapies for gastrointestinal stromal tumors.
Marrari A; Wagner AJ; Hornick JL
Arch Pathol Lab Med; 2012 May; 136(5):483-9. PubMed ID: 22229850
[TBL] [Abstract][Full Text] [Related]
19. Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic GIST patients.
Valadão M; Braggio D; Santos AF; Pimenta-Inada HK; Linhares E; Gonçalves R; Romano S; Vilhena B; Small I; Cubero D; Cruz F; Oliveira AT; Martinho O; Reis RM; Guimarães DP; Ferreira CG
J Surg Res; 2012 Nov; 178(1):288-93. PubMed ID: 22516345
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
